David Schiff, MD, the co-director of UVA Cancer Center’s Neuro-Oncology Center, has authored an editorial in the prestigious New England Journal of Medicine describing the potential significance of the drug vorasidenib for patients with tumors known as “grade 2 IDH-mutant gliomas.” The drug, when tested in the INDIGO clinical trial, was found to slow tumor growth significantly and extended the average time until the tumor started growing from 11.1 months to more than 27 months.
It used to be that we thought of all gliomas as being on a spectrum. We now understand that those with the IDH gene mutation have a markedly different biology, outcome and, as this study shows, vulnerabilities that new therapies can exploit.”Approximately 2,500 Americans are diagnosed with grade 2 IDH-mutant gliomas each year. The median age is only 40. The tumors often affect the patients’ ability to think and hold a job, as well as interfere with other aspects of daily life.
In the INDIGO trial, more than 300 patients were randomized to receive vorasidenib or a harmless placebo. Neither the patients nor their doctors knew which the patients were receiving. Schiff, in his editorial, describes the results as “striking.” Not only did the patients receiving vorasidenib live longer, but they did not need more toxic treatments, such as radiation and chemotherapy, as quickly as the patients receiving placebos.
Source: Healthcare Press (healthcarepress.net)
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NewsMedical - 🏆 19. / 71 Read more »
Source: MENnewsdesk - 🏆 23. / 69 Read more »
Source: Daily_Record - 🏆 9. / 89 Read more »
Source: nottslive - 🏆 96. / 52 Read more »
Source: NewsMedical - 🏆 19. / 71 Read more »
Source: Glasgow_Live - 🏆 4. / 97 Read more »